Relmada Therapeutics Inc

Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that is in Phase 3 clinical trials for the adjunctive or monotherapy treatment of major depressive disorder in adults. Show More...

  • Website https://www.relmada.com
  • Sector Healthcare
  • Industry Biotechnology
  • Last Quote 0.75 USD
  • Last Updated 30-05-2025
  • External Links Yahoo Finance Morningstar Ratios
  •   2009-08 2010-08 2011-08 2012-08 2013-08 2015-06 2016-06 2017-06 2018-06 2019-06 TTM
    Earnings Per Share USD -8.36 -1.04 -2.08 -2.86 -2.74 -1.33
    Dividends USD
    Payout Ratio % *
    Shares Mil 1.0 1.0 2.0 3.0 3.0 3.0 6.0 9.0
    Book Value Per Share * USD 7.45
    Free Cash Flow Per Share * USD
    Return on Assets % -65.66 -234.68 -82.95 -17.18 -96.12 -304.53 -261.05 -24.92
    Financial Leverage (Average) 1.62 2.77 1.45 1.94 1.34 1.02
    Return on Equity % -106.11 -540.52 -37.53 -147.87 -25.63
    Return on Invested Capital % -106.11 -518.96 -36.32 -138.87 -25.58
    Interest Coverage
    Current Ratio 2.62 0.55 1.54 3.04 1.8 0.46 3.83 50.97
    Quick Ratio 1.28 0.45 1.44 2.85 1.49 0.39 3.63 50.85
    Debt/Equity